Patrick Baumhof

This inventor holds 22 USPTO granted patents and 56 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Nucleic Acid Delivery. Top assignees: Curevac Ag, Curevac Se, Qiagen Gmbh. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Baumhof. Retrieved from https://idiyas.com/inventor/patrick-baumhof

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 56)

% Patents Active = 72.7

CIPO Patents = 6 (Patent Applications = 10)

EPO Patents = 13 (Patent Applications = 39)

Average Co-Inventor Count = 2.6

ph-index = 13

Forward Citations = 499(Granted Patents)

Location History:

Hilden, DE (2013 - 2014)
Dusslingen, DE (2012 - 2023)
Tübingen, DE (2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Lipid Nanoparticles

Flavivirus Vaccine

Polymeric Carrier

RNA Compositions

Tumor Treatment

Immunostimulatory Nucleic Acids

Transfection

Peptide Conjugates

Cationic Components

Nucleic Acid Isolation

Thermostable Enzymes

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12589078 - LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS (2026-03-31),

2. 12569549 - Flavivirus vaccine (2026-03-10),

3. 11931406 - Flavivirus vaccine (2024-03-19),

4. 11690910 - Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen (2023-07-04),

5. 11478552 - Hybrid carriers for nucleic acid cargo (2022-10-25),

6. 10918740 - RNA containing composition for treatment of tumor diseases (2021-02-16),

7. 10869935 - RNA containing composition for treatment of tumor diseases (2020-12-22),

8. 10799602 - Method for increasing expression of RNA-encoded proteins (2020-10-13),

9. 10751424 - Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids (2020-08-25),

10. 10568958 - Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates (2020-02-25),

11. 10293060 - Method for increasing expression of RNA-encoded proteins (2019-05-21),

12. 10293058 - RNA containing composition for treatment of tumor diseases (2019-05-21),

13. 10111967 - Complexes of RNA and cationic peptides for transfection and for immunostimulation (2018-10-30),

14. 9907862 - Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids (2018-03-06),

15. 9421255 - Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates (2016-08-23),

Title: Patrick Baumhof: A Pioneer in Flavivirus Research and Vaccination Innovations

Introduction

Patrick Baumhof, based in Dusslingen, Germany, is a distinguished innovator in the field of medical science. With a remarkable portfolio of 20 patents to his name, his work focuses on combatting flavivirus infections, including diseases such as yellow fever and dengue. His recent patents showcase groundbreaking advancements in vaccine development and pharmaceutical compositions aimed at enhancing immune responses.

Latest Patents

Among his latest inventions is a flavivirus vaccine, which encompasses an artificial nucleic acid and a polypeptide designed for the treatment and prevention of flavivirus infections. This invention also includes an immunogenic composition, particularly effective against yellow fever and dengue viruses, along with kits that house these compositions. Another significant patent involves a pharmaceutical composition that features a polymeric carrier cargo complex combined with proteins or peptide antigens relevant to infectious diseases, allergies, autoimmune diseases, and cancer. This innovative combination is poised to foster efficient and adaptive immune responses.

Career Highlights

Patrick Baumhof has contributed his expertise to renowned companies in the biotech sector, including CureVac AG and Qiagen GmbH. His efforts in these organizations have played a pivotal role in advancing vaccine technologies and therapeutic solutions that address critical health challenges.

Collaborations

Throughout his career, Baumhof has collaborated with notable professionals such as Karl-Josef Kallen and Mariola Fotin-Mleczek. These partnerships have been instrumental in fostering innovative research and enhancing the development of effective healthcare solutions.

Conclusion

With a robust body of work that includes 20 patents, Patrick Baumhof exemplifies the spirit of innovation in the medical field. His commitment to advancing vaccination technologies and improving patient outcomes showcases his invaluable contributions to combating viral infections. As research continues to evolve, his inventions may pave the way for new therapies and preventive measures that enhance global health.

Profile summary based on public USPTO records.